The economic burden of systemic lupus erythematosus in Asia: The current state

Lupus

Volumn 19, Issue 12, 2010, Pages 1442-1446

  Mak, A ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Asia; damage; economic burden; lupus; SLE

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ASIA; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE DURATION; HEALTH CARE COST; HOSPITAL COST; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MENTAL HEALTH; NEPHRITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; WORK DISABILITY;

ASIA; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 78649749749     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310374308     Document Type: Review

References (31)

1. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009 ; 5: 400-404.
2. Lau CS, Yin G., Mok MY Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus 2006 ; 15: 715-719.
3. Clarke AE, Petri MA, Manzi S., et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-nation Study Group. J Rheumatol 1999 ; 26: 1500-1511.
4. Clarke AE, Petri M., Manzi S., et al. Tri-nation Study Group. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 2004 ; 43: 1016-1024.
5. Panopalis P., Petri M., Manzi S., et al. Tri-nation Study Group. The systemic lupus erythematosus Tri-nation study: cumulative indirect costs. Arthritis Rheum 2007 ; 57: 64-70.
6. Clarke AE, Esdaile JM, Bloch DA, Lacaille D., Danoff DS, Fries JF A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993 ; 36: 1548-1559.
7. Sutcliffe N., Clarke AE, Taylor R., Frost C., Isenberg DA Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001 ; 40: 37-47.
8. Huscher D., Merkesdal S., Thiele K., Zeidler H., Schneider M., Zink A., German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006 ; 5: 1175-1183.
9. Panopalis P., Yazdany J., Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008 ; 59: 1788-1795.
10. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009 ; 48: 564-568.
11. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009 ; 61: 1159-1167.
12. Partridge AJ, Karlson EW, Daltroy LH, et al. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. Arthritis Rheum 1997 ; 40: 2199-2206.
13. Mok CC, Cheung MY, Ho LY, Yu KL, To CH Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus 2008 ; 17: 1103-1107.
14. Yelin E., Trupin L., Katz P., et al. Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum 2007 ; 57: 56-63.
15. Bertoli AM, Fernández M., Alarcón GS, Vilá LM, Reveille JD Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability. Ann Rheum Dis 2007 ; 66: 12-17.
16. Utset TO, Fink J., Doninger NA Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus. J Rheumatol 2006 ; 33: 531-538.
17. Panopalis P., Julian L., Yazdany J., et al. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum 2007 ; 57: 1453-1460.
18. Baker K., Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology (Oxford) 2009 ; 48: 281-284.
19. Rabbani MA, Habib HB, Islam M., et al. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 2009 ; 18: 848-855.
20. Mok CC, Lau CS Lupus in Hong Kong Chinese. Lupus 2003 ; 12: 717-722.
21. Mok CC, Tang S. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004 ; 117: 791-795.
22. Seligman VA, Lum RF, Olson JL, Li H., Criswell LA Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002 ; 112: 726-729.
23. Li T., Carls GS, Panopalis P., Wang S., Gibson TB, Goetzel RZ Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum 2009 ; 61: 755-763.
24. Karim MY, Pisoni CN, Khamashta MA Update on immunotherapy for systemic lupus erythematosus - what's hot and what's not! Rheumatology (Oxford) 2009 ; 48: 332-341.
25. Ferrera F., Filaci G., Rizzi M., et al. New therapies in SLE. Recent Pat Inflamm Allergy Drug Discov 2008 ; 2: 11-23.
26. Mak A., Cheak AA, Tan JY, Su HC, Ho RC, Lau CS Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009 ; 48: 944-952.
27. Wilson EC, Jayne DR, Dellow E., Fordham RJ The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology (Oxford) 2007 ; 46: 1096-1101.
28. Tse KC, Tang CS, Lam MF, Yap DY, Chan TM Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 2009 ; 36: 76-81.
29. Bachen EA, Chesney MA, Criswell LA Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009 ; 61: 822-829.
30. Curry SL, Levine SB, Jones PK, Kurit DM Medical and psychosocial predictors of sexual outcome among women with systemic lupus erythematosus. Arthritis Care Res 1993 ; 6: 23-30.
31. Zheng Y., Ye DQ, Pan HF, et al. Influence of social support on health-related quality of life in patients with systemic lupus erythematosus. Clin Rheumatol 2009 ; 28: 265-269.